AVDL vs AXSM

For growth investors, Avadel Pharmaceuticals plc (AVDL) is the stronger pick with 504.

8% revenue growth year-over-year, versus 65. 5% for Axsome Therapeutics, Inc. (AXSM). Analysts rate Avadel Pharmaceuticals plc (AVDL) a "Buy" — based on 14 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Axsome Therapeutics, Inc.

(AXSM) delivered a total return of +295. 0%, compared to +174. 6% for Avadel Pharmaceuticals plc (AVDL). Over 10 years, the gap is even starker: AXSM returned +1858% versus AVDL's +99. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Avadel Pharmaceuticals plc (AVDL) is the lower-risk stock at 0.

23β versus Axsome Therapeutics, Inc. 's 0. 69β — meaning AXSM is approximately 202% more volatile than AVDL relative to the S&P 500. On balance sheet safety, Avadel Pharmaceuticals plc (AVDL) carries a lower debt/equity ratio of 2% versus 3% for Axsome Therapeutics, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Avadel Pharmaceuticals plc (AVDL) is pulling ahead at 504.

8% versus 65. 5% for Axsome Therapeutics, Inc. (AXSM). On earnings-per-share growth, the picture is similar: Avadel Pharmaceuticals plc grew EPS 74. 5% year-over-year, compared to 38. 6% for Axsome Therapeutics, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Axsome Therapeutics, Inc.

(AXSM) is the more profitable company, earning -28. 7% net margin versus -28. 9% for Avadel Pharmaceuticals plc — meaning it keeps -28. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: AVDL leads at -25. 1% versus -26. 5% for AXSM. At the gross margin level — before operating expenses — AXSM leads at 92. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for AVDL: 4.

0% to $22. 50.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Axsome Therapeutics, Inc.

(AXSM) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 69), +1858% 10Y return). Both have compounded well over 10 years (AXSM: +1858%, AVDL: +99. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.